ACETO Subsidiary, Rising Pharmaceuticals, to Launch Generic Version of Cleocin Pediatric(R)
PORT WASHINGTON, N.Y., Nov. 26, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, has launched the generic version of the 75mg/*5mL strength of Clindamycin Palmitate Hydrochloride for Oral Solution, USP (Pediatric), an FDA approved generic version of Pfizer Inc.'s Cleocin Pediatric®. According to IMS Health data, U.S. market sales for Clindamycin Palmitate Hydrochloride, which is an antibiotic that is used to treat serious infections caused by bacteria, were approximately $59 million for the twelve months ended June 30, 2012.
ACETO Corporation, incorporated in 1947, is a global leader in the marketing, sale and distribution of products for Human Health (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). With business operations in nine countries, ACETO distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. ACETO's global operations, including a staff of 26 in China and 12 in India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.
This news release contains forward-looking statements as that term is defined in the federal securities laws. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO's reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO's Annual Report or Form 10-K for the fiscal year ended June 30, 2012 and other filings. Copies of these filings are available at www.sec.gov. ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
The ACETO Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13058
CONTACT: Investor Relations Contact: Amy Glynn The Ruth Group (646) 536-7023 firstname.lastname@example.org
- Co-pilot spoke last words heard from missing Malaysian plane |
- U.S., EU impose sanctions after Crimea moves to join Russia |
- Crimeans vote over 90 percent to quit Ukraine for Russia |
- China rejects North Korean crimes report, hits chance of prosecution
- UPDATE 1-Rolls-Royce concurs with Malaysia on missing jet's engine data